The purpose of this study is to determine the frequency of renal and bone toxicity in HIV infected patients receiving antiretroviral therapy, and the outcome in terms of treatment change or/and virological failure, in relation with the presence of classical factors, such as diabetes or hypertension, the role of HIV itself, because of chronic inflammation, and the effects of antiretroviral medication.
This is a retrospective cohort study involving 300 patients to determine the frequency of renal and bone comorbidities/toxicity in a large population of HIV-infected patients receiving antiretroviral therapy, in order to establish the differential role of classical factors, HIV infection, or antiretroviral therapy.
Study Type
OBSERVATIONAL
Enrollment
306
Ramon y Cajal Hospital
Madrid, Madrid, Spain
Incidence of Renal and Bone toxicity
Number and percentage of patients with: * Confirmed estimated glomerular filtration rate (eGFR) by CKD (chronic kidney disease)-epi equation decrease to \< 60 ml/min, or/and * More than 25% of eGFR decrease during therapy, or/and * Tubular toxicity defined as at least two of confirmed proteinuria (\> 300 mg/g), glycosuria with euglycemia, fractional excretion of urinary phosphate \> 20%, or of uric acid \> 10%. AND * Number and percentage of patients with bone mineral density (BMD) decrease \> 10% during follow up or progression to osteopenia (from normal) or to osteoporosis (from osteopenia)
Time frame: Patients will be evaluated for 2 years before
Consequences of renal or bone toxicity
Percentage of patients with regimen discontinuation (any drug in the regimen) because of renal or/and bone toxicity
Time frame: Patients will be evaluated for 2 years before
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.